Lactoferrin conjugated with 40-kDa branched poly(ethylene glycol) has an improved circulating half-life

Pharmaceutical Research

Volumn 26, Issue 9, 2009, Pages 2125-2132

  Nojima, Yasuhiro ^a,d   Suzuki, Yosuke ^a   Yoshida, Kazuhiro ^a   Abe, Fumiko ^a   Shiga, Tuneo ^a   Takeuchi, Takashi ^b   Sugiyama, Akihiko ^b   Shimizu, Hirohiko ^c   Sato, Atsushi ^a  

^a TOKYO UNIVERSITY OF TECHNOLOGY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c NRL Pharma Inc   (Japan)

^d KITASATO UNIVERSITY   (Japan)

Author keywords

Bioactivity; Branched PEG; Lactoferrin; Pharmacokinetics; Stability

Indexed keywords

IRON; LACTOFERRIN; MACROGOL; N HYDROXYSUCCINIMIDE; PROTEINASE;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG HALF LIFE; DRUG PURIFICATION; DRUG SENSITIVITY; DRUG STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ION EXCHANGE CHROMATOGRAPHY; IRON BINDING CAPACITY; MALE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; RAT;

ANIMALS; CHROMATOGRAPHY, ION EXCHANGE; CIRCULAR DICHROISM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HALF-LIFE; LACTOFERRIN; MALE; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 68149163584     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-9925-z     Document Type: Article

References (28)

1. D Caccavo NM Pellegrino M Altamura A Rigon L Amati A Amoroso E Jirillo 2002 Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application J Endotoxin Res. 8 403 17
2. K Yamauchi H Wakabayashi S Hashimoto S Teraguchi H Hayasawa M Tomita 1998 Effects of orally administered bovine lactoferrin on the immune system of healthy volunteers Adv Exp Med Biol. 443 261 5
3. I Mattsby-Baltzer A Roseanu C Motas J Elverfors I Engberg LÅ Hanson 1996 Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells Pediatr Res. 40 257 62
4. L Håversen BG Ohlsson M Hahn-Zoric LÅ Hanson I Mattsby-Baltzer 2002 Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B Cell Immunol. 220 83 95
5. P Valenti G Antonini 2005 Lactoferrin: an important host defence against microbial and viral attack Cell Mol Life Sci. 62 2576 87
6. TJ Ochoa TG Cleary 2009 Effect of lactoferrin on enteric pathogens Biochimie. 91 30 4
7. K Hayashida T Takeuchi H Shimizu K Ando E Harada 2003 Novel function of bovine milk-derived lactoferrin on antinociception mediated by mu-opioid receptor in the rat spinal cord Brain Res. 965 239 45
8. K Hayashida T Takeuchi H Shimizu K Ando E Harada 2003 Lactoferrin enhances opioid-mediated analgesia via nitric oxide in the rat spinal cord Am J Physiol Regul Integr Comp Physiol. 285 R306 12
9. T Takeuchi H Shimizu K Ando E Harada 2004 Bovine lactoferrin reduces plasma triacylglycerol and NEFA accompanied by decreased hepatic cholesterol and triacylglycerol contents in rodents Br J Nutr. 91 533 8
10. TE Lyons MS Miller T Serena P Sheehan L Lavery RS Kirsner DG Armstrong A Reese EW Yankee A Veves 2007 Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study Am J Surg. 193 49 54
11. Y Wang D Raghunadharao G Raman D Doval S Advani P Julka P Parikh S Patil S Nag J Madhavan A Varadhachary 2006 Adding oral talactoferrin to first-line NSCLC chemotherapy safely enhanced efficacy in a randomized trial J Clin Oncol 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 24 7095
12. E Jonasch WM Stadler RM Bukowski TG Hayes A Varadhachary R Malik RA Figlin S Srinivas 2008 Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma Cancer. 113 72 7
13. M Dogru Y Matsumoto Y Yamamoto E Goto M Saiki J Shimazaki T Takebayashi K Tsubota 2007 Lactoferrin in Sjögren's syndrome Ophthalmology. 114 2366 7
14. FM Veronese G Pasut 2005 PEGylation, successful approach to drug delivery Drug Discov Today. 10 1451 8
15. Y Nojima Y Suzuki K Iguchi T Shiga A Iwata T Fujimoto K Yoshida H Shimizu T Takeuchi A Sato 2008 Development of Poly(ethylene glycol) Conjugated Lactoferrin for Oral Administration Bioconjug Chem. 19 2253 9
16. SJ Bell CM Fam EA Chlipala SJ Carlson JI Lee MS Rosendahl DH Doherty GN Cox 2008 Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic Bioconjug Chem. 19 299 305
17. P Bailon A Palleroni CA Schaffer CL Spence WJ Fung JE Porter GK Ehrlich W Pan ZX Xu MW Modi A Farid W Berthold M Graves 2001 Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C Bioconjug Chem. 12 195 202
18. J Ramon V Saez R Baez R Aldana E Hardy 2005 PEGylated interferon-alpha2b: a branched 40 K polyethylene glycol derivative Pharm Res. 22 1374 86
19. YW Jo YS Youn SH Lee BM Kim SH Kang M Yoo EC Choi KC Lee 2006 Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics Int J Pharm. 309 87 93
20. MM Kurfürst 1992 Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis Anal Biochem. 200 244 8
21. K Shimazaki T Hosokawa 1991 A tentative method for rapid preparation of iron-saturated lactoferrin by affinity chromatography Anim Sci Technol (Jpn). 62 354 6
22. CH Kirkpatrick I Green RR Rich AL Schade 1971 Inhibition of growth of Candida albicans by iron-unsaturated lactoferrin: relation to host-defense mechanisms in chronic mucocutaneous candidiasis J Infect Dis. 124 539 44
23. T Takeuchi H Kitagawa E Harada 2004 Evidence of lactoferrin transportation into blood circulation from intestine via lymphatic pathway in adult rats Exp Physiol. 89 263 70
24. BF Anderson HM Baker GE Norris SV Rumball EN Baker 1990 Apolactoferrin structure demonstrates ligand-induced conformational change in transferrins Nature. 344 784 7
25. O Schiavon P Caliceti P Ferruti FM Veronese 2000 Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine) Farmaco. 55 264 9
26. E Elass-Rochard A Roseanu D Legrand M Trif V Salmon C Motas J Montreuil G Spik 1995 Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide Biochem J. 312 839 45
27. AM Di Biase A Pietrantoni A Tinari R Siciliano P Valenti G Antonini L Seganti F Superti 2003 Heparin-interacting sites of bovine lactoferrin are involved in anti-adenovirus activity J Med Virol. 69 495 502
28. PH van Berkel ME Geerts HA van Veen M Mericskay HA de Boer JH Nuijens 1997 N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA Biochem J. 328 145 51